Global CNS correction in a large brain model of human alpha-mannosidosis by intravascular gene therapy

Collapse authors list.
Yoon, Sea Young, Hunter, Jacqueline E, Chawla, Sanjeev, Clarke, Dana L, Molony, Caitlyn, O'Donnell, Patricia A, Bagel, Jessica H, Kumar, Manoj, Poptani, Harish ORCID: 0000-0002-0593-3235, Vite, Charles H et al (show 1 more authors) and Wolfe, John H (2020) Global CNS correction in a large brain model of human alpha-mannosidosis by intravascular gene therapy. BRAIN, 143 (7). pp. 2058-2072.

Text semi-final manuscript; v7 spl-ck changes highlighted_HP.docx - Author Accepted Manuscript Download (215kB)

Abstract

Intravascular injection of certain adeno-associated virus vector serotypes can cross the blood–brain barrier to deliver a gene into the CNS. However, gene distribution has been much more limited within the brains of large animals compared to rodents, rendering this approach suboptimal for treatment of the global brain lesions present in most human neurogenetic diseases. The most commonly used serotype in animal and human studies is 9, which also has the property of being transported via axonal pathways to distal neurons. A small number of other serotypes share this property, three of which were tested intravenously in mice compared to 9. Serotype hu.11 transduced fewer cells in the brain than 9, rh8 was similar to 9, but hu.32 mediated substantially greater transduction than the others throughout the mouse brain. To evaluate the potential for therapeutic application of the hu.32 serotype in a gyrencephalic brain of larger mammals, a hu.32 vector expressing the green fluorescent protein reporter gene was evaluated in the cat. Transduction was widely distributed in the cat brain, including in the cerebral cortex, an important target since mental retardation is an important component of many of the human neurogenetic diseases. The therapeutic potential of a hu.32 serotype vector was evaluated in the cat homologue of the human lysosomal storage disease alpha-mannosidosis, which has globally distributed lysosomal storage lesions in the brain. Treated alpha-mannosidosis cats had reduced severity of neurological signs and extended life spans compared to untreated cats. The extent of therapy was dose dependent and intra-arterial injection was more effective than intravenous delivery. Pre-mortem, non-invasive magnetic resonance spectroscopy and diffusion tensor imaging detected differences between the low and high doses, and showed normalization of grey and white matter imaging parameters at the higher dose. The imaging analysis was corroborated by post-mortem histological analysis, which showed reversal of histopathology throughout the brain with the high dose, intra-arterial treatment. The hu.32 serotype would appear to provide a significant advantage for effective treatment of the gyrencephalic brain by systemic adeno-associated virus delivery in human neurological diseases with widespread brain lesions.

Item Type:	Article
Uncontrolled Keywords:	adeno-associated virus, systemic delivery, global correction, gyrencephalic brain, alpha-mannosidosis
Depositing User:	Symplectic Admin
Date Deposited:	22 Sep 2020 08:08
Last Modified:	18 Jan 2023 23:39
DOI:	10.1093/brain/awaa161
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3095363